JMP Securities Reiterates “Market Outperform” Rating for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating reissued by JMP Securities in a note issued to investors on Tuesday, Benzinga reports. They currently have a $5.00 price target on the stock.

Several other brokerages also recently weighed in on DBVT. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. StockNews.com assumed coverage on shares of DBV Technologies in a research report on Thursday, September 19th. They set a “hold” rating on the stock.

DBV Technologies Trading Up 3.0 %

Shares of DBVT stock traded up $0.02 during trading hours on Tuesday, hitting $0.72. The company’s stock had a trading volume of 583 shares, compared to its average volume of 51,432. The business has a fifty day moving average of $0.87 and a 200-day moving average of $1.09. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $2.82. The stock has a market cap of $69.57 million, a price-to-earnings ratio of -0.86 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. During the same quarter last year, the company posted ($0.26) EPS. On average, equities analysts expect that DBV Technologies will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.